Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Research

Read more breaking news



New vitamin D trials have 'little chance' of showing health benefits, warns analysis


By Nathan Gray+

Last updated on 13-Feb-2014 at 09:08 GMT2014-02-13T09:08:10Z

New vitamin D trials have 'little chance' of showing health benefits, warns analysis

Randomised controlled trials on supplementation with vitamin D seem to show that the vitamin has little causal effect on our health outcomes, according to a new meta-analysis which suggests that future research is 'unlikely' to alter such conclusions.

The study, published in The Lancet Diabetes & Endocrinology, examined the existing evidence from 40 randomised controlled trials - concluding that vitamin D supplementation does not prevent heart attack, stroke, cancer, or bone fractures in the general population by more than 15%.

Led by Dr Mark Bolland from the University of Auckland, New Zealand, the team behind the new analysis added that as a result vitamin D supplements probably provide little, if any, health benefit - and that future randomised trials with similar designs are 'unlikely' to reveal conclusions any different to those already published.

"Findings from observational studies have shown vitamin D insufficiency to be associated with a wide variety of disorders such as fractures, ischaemic heart disease, cerebrovascular disease, and cancer," noted Bolland and his team. "Such findings have led to calls for widespread vitamin D supplementation. However, some researchers have suggested that such recommendations should not be made without supportive trial data, and they have therefore called for randomised controlled trials of vitamin D supplementation with non-skeletal endpoints as primary outcomes."

Bolland and his colleagues used this trial data to perform several types of meta-analysis including a 'futility analysis', which predicts the potential of future study results to sway existing evidence - the results of which indicate that the effect of vitamin D, taken with or without calcium, on heart attack, stroke, cancer, and total fracture lies below a 'futility threshold'. 

"In view of our findings, there is little justification for prescribing vitamin D supplements to prevent myocardial infarction or ischaemic heart disease, stroke or cerebrovascular disease, cancer, or fractures, or to reduce the risk of death in unselected community-dwelling individuals. Investigators and funding bodies should consider the probable futility of undertaking similar trials of vitamin D to investigate any of these endpoints," said the team.

9 comments (Comments are now closed)

Lancet is Biased by Drug Companies

First,the do not discuss the difference between synthetic and Whole Foods..
Investigate for yourselves.Physicians rely on testing and funding thru drug companies.
The bulk of Doctors education is thru these same Big Pharma Groups.

Trust more in the Dr.Andrew Weil's and Dr. Mehmet Oz's who have no dog in the fight.
Drug Companies bottom line is being crushed by an understanding of Whole Foods.
Synthetics are toxic to the body.It was a 1960's ruling by Estes Kefauver making synthetic supplements the standard for testing in the U.S.

We are what we eat,food not chemicals.
William J.Bowers

Report abuse

Posted by William Bowers
14 February 2014 | 16h562014-02-14T16:56:33Z

methodological issues

The choice of D2 or D3 affects results.

The choice of dosing intervals affects results.

The Role of the Parent Compound Vitamin D with
Respect to Metabolism and Function: Why Clinical
Dose Intervals can affect Clinical Outcomes
Bruce W. Hollis, PhD, and Carol L. Wagner, MD
doi: 10.1210/jc.2013-2653 J Clin Endocrinol Metab

The choice of outcomes and sample population affects results.

In one study, they gave D to elderly hospitalized COPD patients (some of whom were still smoking). Really? They expect a Lazarus Effect?

Finally most studies give a standard dose to everybody.

So a 80 pound woman needs the same amount of D as a 250 pound man? A person with a serum level of 5 ng/ml needs the same amount of D as someone with a serum level of 40 ng/ml?

Giving a dose to a population with a bell curve serum distribution results in a new bell curve.

Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency
Osteoporosis International, 02/19/2013, Diamond T et al

Report abuse

Posted by JA Larson
12 February 2014 | 21h482014-02-12T21:48:21Z

Vitamin D3 Study

To Laszlo G Meszaros:

I find the results of your Vitamin D3 study to corroborate what others have found and that the authors of this article have missed- deliberately or not. It is critical that the supplementation of Vitamin D3 be accompanied with a Vitamin K2 complex, which deposits freely circulating calcium in the bloodstream to be deposited on bone rather than on arterial walls, which is one of the causes of arterial rigidity.

Report abuse

Posted by Telekinetic
12 February 2014 | 21h352014-02-12T21:35:25Z

Read all comments (9)

Related products

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Balancing Innovation and Risk in Sports Nutrition Ingredients
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars

Promotional Features